BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Balestracci A, Meni Bataglia L, Toledo I, Beaudoin L, Alvarado C. C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome. Pediatr Nephrol 2020;35:331-9. [PMID: 31475299 DOI: 10.1007/s00467-019-04334-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Goldstein J, Nuñez-Goluboay K, Pinto A. Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli. Curr Neuropharmacol 2021;19:24-44. [PMID: 32077828 DOI: 10.2174/1570159X18666200220143001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
3 Loos S, Oh J, van de Loo L, Kemper MJ, Blohm M, Schild R. Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2021. [PMID: 34046736 DOI: 10.1007/s00467-021-05108-6] [Reference Citation Analysis]